Keith Crandell at ARCH Venture Partners follows a "follow the science" approach that prioritizes backing powerful scientific platforms first rather than starting with defined market needs, believing important applications will emerge from sufficiently strong science. He brings a tools-focused perspective to biotech investing, drawing analogies to the semiconductor industry's measurement revolution and emphasizing that better, faster, cheaper measurements are the key enablers for biotech progress. Keith Crandell at ARCH Venture Partners follows a "follow the science" approach that prioritizes backing powerful scientific platforms first rather than starting with defined market needs, believing important applications will emerge from sufficiently strong science. He brings a tools-focused perspective to biotech investing, drawing analogies to the semiconductor industry's measurement revolution and emphasizing that better, faster, cheaper measurements are the key enablers for biotech progress.